United Therapeutics Corporation - Common Stock (NQ:UTHR)

539.98 -5.02 (-0.92%)

Delayed Quote Updated: 2:58 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

3 Biotech Stocks on Track for 50% Returns (or More) by 2028 ↗

August 04, 2024

Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028!

Via InvestorPlace

UTHR Stock Earnings: United Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗

July 31, 2024

UTHR stock results show that United Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

United Therapeutics Stock Skids On Mixed Second-Quarter Results ↗

July 31, 2024

The company's earnings came in far below expectations, though sales easily beat.

Via Investor's Business Daily

United Therapeutics Corporation Reports Second Quarter 2024 Financial Results

July 31, 2024

From United Therapeutics Corporation

Via Business Wire

The 3 Best 3D Bioprinting Stocks to Buy Now ↗

July 26, 2024

These are three of the best 3D bioprinting stocks to buy as the technology begins to hit its stride in the health care sector.

Via InvestorPlace

Navigating 9 Analyst Ratings For United Therapeutics ↗

July 25, 2024

Via Benzinga

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $28,000 Today ↗

July 16, 2024

Via Benzinga

Unveiling 6 Analyst Insights On United Therapeutics ↗

July 08, 2024

Via Benzinga

Deep Dive Into United Therapeutics Stock: Analyst Perspectives (5 Ratings) ↗

June 12, 2024

Via Benzinga

Beam Therapeutics Stock Earns RS Rating Jump To 85 ↗

July 24, 2024

On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85.

Via Investor's Business Daily

United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024

July 24, 2024

From United Therapeutics Corporation

Via Business Wire

Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today ↗

July 22, 2024

Via Benzinga

Biotech Arvinas Stock Earns 82 RS Rating ↗

July 17, 2024

The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82.

Via Investor's Business Daily

Don't overlook NASDAQ:UTHR—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

July 17, 2024

Despite its impressive fundamentals, UNITED THERAPEUTICS CORP (NASDAQ:UTHR) remains undervalued.

Via Chartmill

Denali Therapeutics Stock Gets Technical Rating Upgrade ↗

July 16, 2024

Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

3 Biotech Stocks to Buy Now: Q3 Edition ↗

July 15, 2024

Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry.

Via InvestorPlace

United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

July 10, 2024

From United Therapeutics Corporation

Via Business Wire

3 Undervalued Stocks on Track to Double (or More) by 2028 ↗

July 08, 2024

The stock market is on the brink of a multi-year bull market. Consider these undervalued growth stocks to buy that can double or more by 2028.

Via InvestorPlace

Members of Congress Buy and Sell Stocks. These ETFs Let You Invest Like Democrats or Republicans. ↗

July 02, 2024

Whether you'd like to invest like Nancy Pelosi or Ted Cruz, you can. But maybe you shouldn't.

Via The Motley Fool

Topics ETFs

7 Undervalued Biotech Stocks to Buy for Big-Time Returns ↗

July 01, 2024

The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.

Via InvestorPlace

Chart Of The Day: United Therapeutics - Drugs For Chronic Illnesses ↗

June 28, 2024

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening...

Via Talk Markets

UroGen Pharma Stock Earns 91 RS Rating ↗

June 27, 2024

UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.

Via Investor's Business Daily

United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors

June 27, 2024

From United Therapeutics Corporation

Via Business Wire

When you look at NASDAQ:UTHR, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

June 26, 2024

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Arcellx Stock Earns Relative Strength Rating Upgrade ↗

June 21, 2024

One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.

Via Investor's Business Daily

The 3 Best Medical Device Stocks to Buy in June 2024 ↗

June 20, 2024

Medical devices are at the forefront of the digitalization of medicine. making these the three best medical device stocks to buy.

Via InvestorPlace

Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗

June 20, 2024

Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

June 19, 2024

Via Benzinga

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗

June 14, 2024

Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.

Via Investor's Business Daily

Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade ↗

June 12, 2024

On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.

Via Investor's Business Daily

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.